Siemens AG said Tuesday it will partner with biopharmaceutical manufacturer Exyte to construct biotech facilities to mass produce new medicines as countries emerge from coronavirus lockdown.
The German engineering group said the first buildings are being designed for cell- and gene-therapy manufacturing and biologicals production in China and Europe.
"We are excited to collaborate with Exyte to provide prefabricated, modular biotechnology solutions with our technology already embedded," said Eckard Eberle, chief executive of Siemens Process Automation.
Write to Jessica Sier at jessica.sier@wsj.com
"smart" - Google News
June 09, 2020 at 01:41PM
https://ift.tt/2AkjRGr
Siemens partners with Exyte over smart biotech - MarketWatch
"smart" - Google News
https://ift.tt/2P2kUhG
https://ift.tt/3febf3M
Bagikan Berita Ini
0 Response to "Siemens partners with Exyte over smart biotech - MarketWatch"
Post a Comment